Tern Plc confirms no banking relationship with Silicon Valley Bank

TERN Plc

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, provides the following statement regarding Silicon Valley Bank and Silicon Valley Bank UK Limited.

Tern confirms that the Company has no banking relationship, or other financing arrangements, with SVB.

While Tern Plc continues to monitor the SVB situation and its effect on Tern’s portfolio companies, the Directors of Tern do not currently believe that any of the portfolio companies’ exposure to SVB will have a significant impact on the net asset value of Tern.

Further announcements will be made, as necessary and appropriate, in due course.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets a core security gap in healthcare

Device Authority says healthcare must secure legacy medical devices by putting trusted device identity at the centre of cybersecurity strategy.

Evidence-based personas put behaviour at the centre of customer intelligence

Evidence-based personas shift customer intelligence from what people might say to what they are likely to do.

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Search